Crystal form of muscarine antagonist, method for preparing same, and use thereof
By developing crystal form A in the form of refenacin free alkali, the harsh conditions and difficult problems of existing refenacin crystal form in industrial production are solved, and high purity and high yield preparation is achieved, which is suitable for Treatment of chronic obstructive pulmonary disease.
Patent Information
- Application Number
- PCT/CN2024/090925
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-01-23
- Filing Date
- 2024-04-30
- Publication Date
- 2024-11-14
AI Technical Summary
The crystalline conditions of existing refenaxin form type I, II and IV are harsh, and are not suitable for industrial production, and are difficult to remove impurities. The crystallization process of Form III in acetonitrile is complex and has a low yield, making it difficult to develop. A new crystal form that is stable and easy to industrially amplify.
Provides free alkali form crystal A of rafenacin, containing crystal water, has a regular flake appearance, high crystallinity, suitable for rapid dissolution in inhaled solution, and is prepared by a mixed solvent of ethanol/water or acetone/water, using Specific temperature and dropping steps ensure high purity and high yield.
Achieved high-purity and low-cost rappenacin crystal A preparation, with a regular appearance, large particle size and fast dissolution rate. It is suitable for industrial production. The product purity is higher than 99.5%, the yield is ≥90%, and the process is robust, which is suitable for Used for the treatment of chronic obstructive pulmonary disease.
Smart Images

Figure CN2024090925_14112024_PF_FP_ABST
Abstract
Description
Crystal form of muscarinic antagonist and its preparation method and use Technical Field
[0001] The present invention belongs to the field of drug crystal forms, relates to crystal forms of muscarinic antagonists, preparation methods and uses thereof, and particularly relates to crystal forms of revenacin and a preparation method thereof. Background Art
[0002] Revenacin, whose chemical name is 1-(2-(4-(((4-carbamoylpiperidin-1-yl)methyl)-N-methylbenzamido)ethyl)piperidin-4-yl[1,1'-biphenyl]-2-ylcarbamate. Its structural formula is as follows:
[0003] Revenacin is a novel biphenyl compound with muscarinic receptor antagonist or anticholinergic activity. It blocks the M3 receptors on airway smooth muscle, preventing acetylcholine-induced bronchoconstriction and thus promoting bronchodilator effects. In November 2018, the U.S. Food and Drug Administration (FDA) approved the inhalation solution of Revenacin for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
[0004] There are numerous reports on the solid forms of revenacin. U.S. patent application US2007 / 0112027 discloses the crystal forms of revenacin free base hydrate, Form I and Form II, and Chinese patent application CN 102470130A discloses two crystal forms of revenacin free base anhydrate, Form III and Form IV. Among the various revenacin crystal forms, Forms I, II, and IV require stringent crystallization conditions, making them unsuitable for industrial production and scale-up. Furthermore, Form I exhibits agglomerated crystal morphology (see Figure 22 of patent application CN 101163677A), making production and impurity removal difficult and resulting in poor process flow. Form III undergoes a complex crystallization process in acetonitrile and yields a relatively low 75%. Crystallization yields can be increased to over 90% in toluene, but toluene is a Class II solvent and can easily exceed the standard for residual solvent residues as a crystallization solvent. For solution inhalation formulations, there is a need to develop new crystal forms that are relatively stable, have simple crystallization processes, are easily scalable, and exhibit low hygroscopicity.
[0005] Summary of the Invention
[0006] The first aspect of the present invention provides revenacin crystal form A, which is a free base form containing crystalline water. The water content is 8.0% to 10% by weight within a humidity range of 30% to 90%. When placed under a humidity condition of 80% ± 2% for 24 hours, the weight gain due to moisture absorption is less than 2%. The crystal form has a regular flaky appearance, high crystallinity, and a relatively fast dissolution rate during the preparation of an inhalation solution.
[0007] The X-ray powder diffraction pattern of the revenacin crystal form A of the present invention has characteristic peaks at diffraction angles 2θ of 4.7±0.2°, 9.2±0.2°, 12.7±0.2°, 18.2±0.2°, 18.5±0.2°, 20.7±0.2°, 21.3±0.2° and 25.6±0.2°.
[0008] In some embodiments of the present invention, the X-ray powder diffraction pattern of the revenacin crystalline form A further has at least one characteristic peak at a diffraction angle 2θ of 13.3±0.2°, 13.7±0.2°, 14.0±0.2°, 16.1±0.2°, 16.7±0.2°, 17.4±0.2°, 18.8±0.2°, 19.4±0.2°, 22.1±0.2°, 22.3±0.2°, 23.0±0.2°, 24.2±0.2° and 33.5±0.2°, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 characteristic peaks.
[0009] In some embodiments of the present invention, the X-ray powder diffraction pattern of revenacin crystalline form A has characteristic peaks at diffraction angles 2θ of 4.7±0.2°, 9.2±0.2°, 12.7±0.2°, 13.3±0.2°, 13.7±0.2°, 14.0±0.2°, 16.1±0.2°, 16.7±0.2°, 17.4±0.2°, 18.2±0.2°, 18.5±0.2°, 18.8±0.2°, 19.4±0.2°, 20.7±0.2°, 21.3±0.2°, 22.1±0.2°, 22.3±0.2°, 23.0±0.2°, 24.2±0.2°, 25.6±0.2° and 33.5±0.2°.
[0010] In some embodiments of the present invention, the X-ray powder diffraction pattern of the revenacin crystalline form A further has at least one characteristic peak at diffraction angles 2θ of 8.9±0.2°, 9.6±0.2°, 9.8±0.2°, 20.1±0.2°, 23.3±0.2°, 26.4±0.2°, 26.9±0.2°, 27.6±0.2°, 28.5±0.2°, 29.1±0.2°, 29.4±0.2°, 30.1±0.2° and 32.9±0.2°, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 characteristic peaks.
[0011] In some embodiments of the present invention, the X-ray powder diffraction pattern of revenacin crystalline form A is 4.7±0.2°, 8.9±0.2°, 9.2±0.2°, 9.6±0.2°, 9.8±0.2°, 12.7±0.2°, 13.3±0.2°, 13.7±0.2°, 14.0±0.2°, 16.1±0.2°, 16.7±0.2°, 17.4±0.2°, 18.2±0.2°, 18.5±0.2°, 18.8±0.2°, 19.4±0. .2°, 20.1±0.2°, 20.7±0.2°, 21.3±0.2°, 22.1±0.2°, 22.3±0.2°, 23.0±0.2°, 23.3±0.2°, 24.2±0.2°, 25.6±0.2°, 26.4±0.2°, 26.9±0.2°, 27.6±0.2°, 28.5±0.2°, 29.1±0.2°, 29.4±0.2°, 30.1±0.2°, 32.9±0.2° and 33.5±0.2°.
[0012] In some embodiments of the present invention, the X-ray powder diffraction pattern of revenacin crystalline form A is substantially as shown in FIG1 .
[0013] In some embodiments of the present invention, the X-ray powder diffraction pattern of revenacin crystal form A is shown in FIG1 .
[0014] In some embodiments of the present invention, the revenacin crystal form A contains crystal water and is a hydrate crystal form, and the water content according to the Karl Fischer (KF) test is 8.0 wt% to 10 wt%.
[0015] In some embodiments of the present invention, the revenacin crystalline form A is revenacin trihydrate.
[0016] In some embodiments of the present invention, revenacin crystal form A has an endothermic peak between 85-125°C, and the onset temperature value (onset value) of the endothermic peak is 88.3°C±5°C.
[0017] In some embodiments of the present invention, the DSC curve of revenacin form A is substantially as shown in FIG2 .
[0018] In some embodiments of the present invention, the DSC curve of revenacin crystal form A is shown in FIG2 .
[0019] In some embodiments of the present invention, the weight loss of revenacin crystal form A is 9.2±0.2% in the temperature range of 35-100°C.
[0020] In some embodiments of the present invention, the TGA curve of revenacin form A is substantially as shown in FIG3 .
[0021] In some embodiments of the present invention, the TGA curve of revenacin crystal form A is shown in FIG3 .
[0022] In some embodiments of the present invention, the appearance of revenacin crystal form A is regular flakes.
[0023] In some embodiments of the present invention, a polarizing microscopy (PLM) image of revenacin crystal form A is shown in FIG4 .
[0024] The second aspect of the present invention provides a single crystal of revenacin hydrate, which belongs to the triclinic system, has a space group of P-1, and its crystal axis The angles between the crystal planes are α=86.419(4)°, β=86.906(4)°, and γ=89.544(3)°. The number of asymmetric units in the unit cell is Z, which is 2. Each unit cell contains one refenacin molecule and three water molecules.
[0025] The third aspect of the present invention provides a method for preparing revenacin crystal form A, comprising the following steps:
[0026] Step 1: mixing revenacin with a dissolving solvent, stirring, heating, and dissolving. The dissolving solvent is a mixed solvent of ethanol / water or a mixed solvent of acetone / water, for example, the dissolving solvent is a mixed solvent of ethanol / water;
[0027] Step 2: Cooling to 35-45°C and stirring to grow crystals to obtain a refenacin suspension solution;
[0028] Step 3: adding the precipitation solvent dropwise to the suspension solution in step 2 at 35-45°C; and
[0029] Step 4: After cooling to 0-25°C and growing the crystals, the mixture is filtered and dried to a constant weight to obtain the revenacin crystal form A.
[0030] In some embodiments of the present invention, in the above preparation method, the mass volume ratio of revenacin to the dissolving solvent in step 1 is 1:4-5 in g / mL.
[0031] In some embodiments of the present invention, in the above preparation method, in step 1, revenacin is added to the dissolving solvent with stirring and the temperature is raised to 50-55° C. to dissolve clearly.
[0032] In some embodiments of the present invention, in the above preparation method, the dissolving solvent is a mixed solvent of ethanol / water, preferably the dissolving solvent is a mixed solvent of ethanol and water in a volume ratio of 1-2:1, preferably a volume ratio of 2:1 or 1:1.
[0033] In some embodiments of the present invention, in the above preparation method, the dissolving solvent is a mixed solvent of acetone / water, preferably the dissolving solvent is a mixed solvent of acetone and water in a volume ratio of 1-4:1, preferably a volume ratio of 2-4:1, for example, a volume ratio of 4:1, 3:1 or 2:1.
[0034] In some embodiments of the present invention, in the above preparation method, revenacin form A seed crystals are added in step 2.
[0035] In some embodiments of the present invention, in the above preparation method, the amount of seed crystals added in step 2 is 1% to 2% by weight of revenacin, preferably 1% by weight.
[0036] In some embodiments of the present invention, in the above preparation method, the time for growing the crystal with heat preservation and stirring in step 2 is 1-4 hours, preferably 2 hours; the stirring rate is 100-800 rpm, preferably 400-600 rpm.
[0037] In some embodiments of the present invention, in the above preparation method, the precipitation solvent in step three is a mixed solvent of ethanol and water, preferably a mixed solvent in which the volume ratio of ethanol to water is 1:3-5, for example, a mixed solvent in which the volume ratio of ethanol to water is 1:3, 1:4 or 1:5.
[0038] In some embodiments of the present invention, in the above preparation method, the precipitation solvent in step 3 is a mixed solvent of acetone / water, preferably a mixed solvent with a volume ratio of acetone to water of 1:3-5, for example, a mixed solvent with a volume ratio of acetone to water of 1:3, 1:4 or 1:5.
[0039] In some embodiments of the present invention, in the above preparation method, the dissolving solvent is a mixed solvent of ethanol / water, preferably a mixed solvent having a volume ratio of ethanol to water of 1-2:1, for example, a mixed solvent having a volume ratio of ethanol to water of 2:1 or 1:1;
[0040] The precipitation solvent in step 3 is a mixed solvent of ethanol and water, preferably a mixed solvent with a volume ratio of ethanol to water of 1:3-5, for example, a mixed solvent with a volume ratio of ethanol to water of 1:3, 1:4 or 1:5.
[0041] In some embodiments of the present invention, in the above preparation method, the dissolving solvent is a mixed solvent of acetone / water, preferably a mixed solvent of acetone and water in a volume ratio of 1-4:1, preferably a volume ratio of 2-4:1, for example, a volume ratio of 4:1, 3:1 or 2:1;
[0042] The precipitation solvent in step 3 is a mixed solvent of acetone / water, preferably a mixed solvent with a volume ratio of acetone to water of 1:3-5, for example, a mixed solvent with a volume ratio of acetone to water of 1:3, 1:4 or 1:5.
[0043] In some embodiments of the present invention, in the above preparation method, the mass volume ratio of revenacin to the precipitated solvent in step 3, in g / mL, is 1:3-6, preferably 1:4.
[0044] In some embodiments of the present invention, in the above preparation method, the dropwise addition rate of the precipitation solvent in step 3 is nonlinear, and the dropwise addition acceleration is slow at first and then fast; preferably, the dropwise addition time is 2-6 hours; more preferably, the dropwise addition time is 3-4 hours.
[0045] In some embodiments of the present invention, in the above preparation method, the crystal growing time in step 4 is 1-10 hours.
[0046] In some embodiments of the present invention, in the above preparation method, the cooling rate in step 4 is 0.1-2°C / min, preferably 0.5°C / min.
[0047] In some embodiments of the present invention, in the above preparation method, the drying in step 4 is carried out at a temperature of 25-45° C. and a vacuum degree of 0.08 MPa-0.1 MPa for 2-20 hours.
[0048] A fourth aspect of the present invention provides a method for preparing a revenacin hydrate single crystal, comprising the following steps:
[0049] Step 1: adding an excess of refenacin to an acetone / water solution, mixing, and filtering to obtain a saturated refenacin solution; and
[0050] Step 2: diluting the saturated solution of refenacin with an acetone / water solution, standing and evaporating, and obtaining the refenacin hydrate single crystal.
[0051] In some embodiments of the present invention, in the above preparation method, the volume ratio of acetone to water in the acetone / water solution in steps 1 and 2 is 5-7:1, for example, 5:1, 6:1 or 7:1.
[0052] In some embodiments of the present invention, in the above preparation method, filtration is performed in step 1 through a needle filter membrane, preferably a 0.25 μm needle filter membrane.
[0053] In some embodiments of the present invention, in the above preparation method, the volume ratio of the saturated refenacin solution to the acetone / water solution in step 2 is 1:8-10, preferably 1:9.
[0054] The fifth aspect of the present invention provides a pharmaceutical composition comprising the revifenacin crystal form A of the first aspect of the present invention or the revifenacin hydrate single crystal of the second aspect of the present invention, and one or more pharmaceutically acceptable carriers.
[0055] In some embodiments of the present invention, the pharmaceutical composition optionally contains one or more "other therapeutic agents", which refer to substances other than revulfenacin that have pharmacological activity, such as other muscarinic receptor antagonists or anticholinergic activities that can have a synergistic therapeutic effect with revulfenacin.
[0056] Pharmaceutically acceptable carriers can be selected from the following: fillers (diluents), binders, wetting agents, disintegrants, or excipients. The unit dosage form of the pharmaceutical composition can be tablets, capsules, cachets, bottled solutions, powders, granules, emulsions, lozenges, suppositories, reconstituted powders, or liquid formulations. Depending on the method of administration, the composition can contain 0.1 to 99% by weight of the active compound. In some embodiments, the unit dosage of the pharmaceutical composition is 0.001 mg to 1000 mg.
[0057] The sixth aspect of the present invention provides use of the revenacin crystal form A of the first aspect of the present invention, the revenacin hydrate single crystal of the second aspect of the present invention, or the pharmaceutical composition of the fifth aspect in the preparation of a medicament for treating chronic obstructive pulmonary disease.
[0058] The seventh aspect of the present invention provides the revifenacin crystal form A of the first aspect of the present invention, the revifenacin hydrate single crystal of the second aspect of the present invention, or the pharmaceutical composition of the fifth aspect, for use in treating chronic obstructive pulmonary disease.
[0059] The eighth aspect of the present invention provides a method for treating chronic obstructive pulmonary disease, comprising administering to a subject in need thereof a therapeutically effective amount of the revenacin crystalline form A of the first aspect of the present invention, the revenacin hydrate single crystal of the second aspect of the present invention, or the pharmaceutical composition of the fifth aspect.
[0060] The present invention has the following beneficial effects:
[0061] The crystal form of the present invention has a regular flaky appearance, high crystallinity, large particle size, excellent powder properties, fast dissolution rate, high fluidity and bulk density; it is easy to crush, low in cost, and easier to implement on a commercial industrial scale.
[0062] The preparation method of the present invention has simple and efficient operation steps, can effectively avoid oil production during the crystallization process, and is less time-consuming and energy-consuming; the product purity is higher than 99.5%; the yield is ≥90.0%; the process is relatively robust, reproducible, and the crystal form is consistent between batches. BRIEF DESCRIPTION OF THE DRAWINGS
[0063] FIG1 is an X-ray powder diffraction (XRPD) pattern of crystalline form A of revenacin.
[0064] FIG2 is the DSC spectrum of revenacin crystal form A.
[0065] FIG3 is a TGA spectrum of revenacin crystal form A.
[0066] FIG4 is a polarizing microscope PLM image (50 times) of revenacin crystal form A.
[0067] FIG5 is a dynamic water sorption / desorption spectrum (DVS) of revenacin form A.
[0068] FIG6 is the XRPD patterns of revenacin with different water contents. From bottom to top, the curves are the XRPD curves of revenacin with KF water contents of 17 wt %, 8.9 wt %, 8.3 wt % and 7.1 wt %, respectively.
[0069] Figure 7 XRPD pattern of temperature and humidity mediated crystal transformation of revenacin form A.
[0070] Figure 8 XRPD patterns of revenacin form A after accelerated and long-term storage.
[0071] FIG9 is a diagram showing the single crystal structure of a single crystal of revenacin hydrate.
[0072] Figure 10 XRD pattern of revenacin single crystal simulated and calculated.
[0073] Figure 11 Particle size distribution of revenacin crystal form A. DETAILED DESCRIPTION
[0074] The present invention is further described below through examples. The examples of the present invention are only used to illustrate the technical solutions of the present invention and are not used to limit the scope of the present invention. Those skilled in the art may make some non-essential improvements and adjustments, which still fall within the scope of protection of the present invention.
[0075] definition
[0076] Unless otherwise stated, all technical terms and scientific terms used herein have the same meaning as those generally understood by those skilled in the art to which the present invention belongs. If there is a contradiction, the definition herein shall prevail. When a certain amount, concentration or other value or parameter is expressed in the form of a range, a preferred range or a preferred upper numerical limit and a preferred lower numerical limit, it should be understood that it is equivalent to specifically revealing any range by combining any pair of upper range limits or preferred numerical values with any lower range limit or preferred numerical value. Unless otherwise stated, the numerical ranges listed herein are intended to include the endpoints of the range and all integers and fractions (decimals) within the range.
[0077] The term "about" when used in conjunction with a numerical variable generally means that the value of that variable and all values of that variable are within experimental error (e.g., within a 95% confidence interval for the mean) or within a range of ±20%, ±10%, ±5%, or ±2% of the stated value.
[0078] The term "comprising" or its synonyms "including," "containing," and "having" are open ended and do not exclude additional unrecited elements, steps, or ingredients. The expression "consisting of excludes any element, step, or ingredient not specified. The term "consisting essentially of" means that the scope is limited to the specified elements, steps, or ingredients, plus any optional elements, steps, or ingredients that do not materially affect the basic and novel characteristics of the claimed subject matter. It should be understood that the term "comprising" and similar terms encompass the terms "consisting essentially of" and "consisting of."
[0079] As used herein, the term "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes both occurring and not occurring.
[0080] Unless otherwise indicated, percentages, parts, etc. herein are by weight.
[0081] As used herein, the term "crystalline form" or "crystal" refers to any solid material that exhibits a three-dimensional ordering, as opposed to amorphous solid material, which produces a characteristic XRPD pattern with well-defined peaks.
[0082] As used herein, the term "seed crystals" refers to an additive that forms a crystal nucleus in a crystallization process, thereby accelerating or promoting the growth of crystals of the same enantiomer as the crystal form or stereoconfiguration.
[0083] As used herein, the term "X-ray powder diffraction pattern" or "XRPD pattern" refers to an experimentally observed diffraction pattern or a parameter, data or value derived therefrom. An XRPD pattern is typically characterized by peak positions (abscissa) and / or peak intensities (ordinate).
[0084] As used herein, the term "diffraction angle" or "2θ" refers to the peak position expressed in degrees (°) based on the setup in the X-ray diffraction experiment, and is generally the unit of the abscissa in the diffraction pattern. If the reflection is diffracted when the incident beam forms an angle θ with a certain lattice plane, the experimental setup requires that the reflected beam be recorded at an angle 2θ. It should be understood that the specific 2θ value of a specific crystalline form mentioned herein is intended to represent the 2θ value (expressed in degrees) measured using the X-ray diffraction experimental conditions described herein. For example, as described herein, using Cu-Kα (Kα1( The XRPD patterns herein are preferably acquired on a PANalytacal X'Pert3 Powder X-ray powder diffraction analyzer, and the transmission mode is preferably acquired on a PANalytacal X'Pert3 Powder X-ray powder diffraction analyzer.
[0085] As used herein, the term "substantially the same" or "substantially as shown in Figure X" with respect to X-ray diffraction peaks means that variations in representative peak positions and intensities are taken into account. For example, one skilled in the art will appreciate that peak positions (2θ) will exhibit some variation, typically as much as 0.1 to 0.2 degrees, and that the instrument used to measure diffraction will also introduce some variation. In addition, one skilled in the art will appreciate that relative peak intensities will vary due to instrumental variations, as well as the degree of crystallinity, preferred orientation, the surface of the sample being prepared, and other factors known to one skilled in the art.
[0086] Similarly, as used herein, "substantially as shown in Figure X" with respect to DSC and TGA patterns is also intended to encompass variations associated with these analytical techniques known to those skilled in the art. For example, for well-defined peaks in a DSC pattern, variations of up to ±5°C are common, and even greater (e.g., up to ±10°C) for broad peaks.
[0087] As used herein, the term "room temperature" refers to 20°C ± 5°C.
[0088] Characterization of crystalline forms
[0089] The crystalline form prepared in the example was characterized by X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), polarizing microscopy (PLM) and dynamic water sorption analysis (DVS).
[0090] (1) X-ray powder diffraction (XRPD):
[0091] XRPD patterns of the crystalline form were collected using an X`Pert3 Powder diffractometer, using Cu-palladium irradiation and absolute scan detection at room temperature. The detection range was 3.5° to 40°, with a step size of 0.013°, a dwell time of 50 s, and a single scan.
[0092] (2)DSC
[0093] DSC spectra of the crystalline form were collected using a TA DSC2500 differential scanning calorimeter. The test temperature range was 35°C to 150°C, with a heating rate of 10°C / min. Nitrogen was purged at a flow rate of 50 mL / min during the test.
[0094] (3)TGA
[0095] TGA patterns of the crystalline form were collected using a METTLER TOLEDO TGA 1. The test temperature range was 35°C to 500°C, with a heating rate of 10°C / min. Nitrogen was used for purging at a flow rate of 50 mL / min.
[0096] (4)DVS
[0097] The DVS spectrum of the crystal form was tested using DVS Intrinsic (SMS) at a test temperature of 25°C in cycle-DMDT mode.
[0098] (5) Particle size analysis
[0099] Powder particle size data was analyzed using a Malvern Mastersizer 3000 laser particle size analyzer, using the third method of Part 0982 of the 2020 edition of the Chinese Pharmacopoeia (Chinese Pharmacopoeia). The particle size distribution of revenacin Form A was determined using the following parameters: non-spherical particle type, a refractive index of 1.52, an absorptivity of 0.001, a rotational speed of 1800 rpm, an opacity of 2%-15%, a sample background test time of 10 seconds, a dispersion solvent of water, a dispersant refractive index of 1.330, a stabilization time of approximately 30 seconds, and three tests.
[0100] (6) Bulk density, tap density and angle of repose analysis
[0101] The bulk and tap densities of revenacin Form A were determined using a powder density tester (model HY-100, manufactured by Dandong Haoyu Technology Co., Ltd.), referring to the requirements of "0993 Bulk Density and Tap Density" in the General Chapter of Part IV of the 2020 Pharmacopoeia. Test method: Weigh an appropriate amount of Form A sample and slowly pour it into a 50mL graduated glass cylinder. Carefully scrape the top and record the apparent volume. The cylinder is then placed on a powder density meter and shaken at a frequency of 1250. The tapped volume is recorded and the tap density is calculated. Three parallel tests are performed on the same batch of samples.
[0102] The angle of repose of Form A of revenacin was measured using a powder comprehensive properties tester (Dandong Better Instruments, Model BT-1000). The test method: Weigh an appropriate amount of Form A sample and pour it into a funnel. The powder falls through the funnel, forming a cone. The angle between the inclined plane and the horizontal plane is measured, and this is repeated three times in parallel.
[0103] Example 1:
[0104] 90g of revenacin (which can be synthesized according to the method of Example 2 and Example 3 of patent application CN102958916A) and 360mL of ethanol / water mixed solvent (ethanol: water volume ratio of 1:1) are mixed and heated to 50°C to dissolve. Then, after cooling to 45°C, 0.1g of seed crystals are added. After crystallization, 360mL of precipitation solvent (ethanol: water volume ratio of 1:3) is slowly added dropwise. After the addition is completed, the temperature is cooled to 25°C for crystallization, filtered, and the filter cake is rinsed twice with 400mL of ethanol / water mixed solvent (ethanol: water volume ratio of 1:3). Finally, the obtained wet crystal product is dried at 30°C and a vacuum degree of 0.1Mpa for 20h to obtain revenacin crystal form A 82.3g, HPLC chemical purity is 99.9%, yield is 91.4%, and Karl Fischer test water content is 9.4% by weight.
[0105] The XRPD pattern of revenacin form A is shown in Figure 1, and the XRPD peak positions and relative peak intensities are shown in the following table:
[0106] The thermal analysis DSC spectrum of revenacin Form A is shown in Figure 2, with the onset temperature (onset value) of the endothermic peak at 88.3°C. The TGA of revenacin Form A is shown in Figure 3, with a weight loss of 9.2% due to dehydrated water. A polarizing microscope image of revenacin Form A is shown in Figure 4.
[0107] Example 1-1:
[0108] 2 g of refenacin and 10 mL of an acetone / water mixed solvent (acetone: water volume ratio of 3:1) were mixed and heated to 55°C to dissolve. The mixture was then cooled to 38°C, 0.02 g of seed crystals were added, and after growing the crystals, 8 mL of a precipitation solvent (acetone: water volume ratio of 1:3) was slowly added dropwise. After the addition was complete, the mixture was cooled to 25°C to grow the crystals, filtered, and the filter cake was rinsed twice with 10 mL of an acetone / water mixed solvent (acetone: water volume ratio of 1:3). The wet crystal product was dried at 25°C and a vacuum degree of 0.1 MPa for 10 h to obtain 1.85 g of refenacin Form A with a chemical purity of 99.79% and a yield of 92.5%.
[0109] The X-ray powder diffraction pattern, DSC pattern, TGA pattern and polarizing microscope image of the obtained refenacin crystal form A were basically consistent with those in Example 1; the water content in the Karl Fischer test was 9.5% by weight.
[0110] The XRPD peak positions and relative peak intensities of revenacin form A are shown in the following table:
[0111] Example 2:
[0112] 2g of revenacin and 10mL of an ethanol / water mixture (5:4 ethanol:water by volume) were mixed and heated to 55°C to dissolve. The mixture was then cooled to 44°C, and 0.02g of seed crystals were added. After crystallization, 8mL of a precipitation solvent (1:5 ethanol:water by volume) was slowly added dropwise. After the addition was complete, the mixture was cooled to 25°C and crystallized. The mixture was then filtered and rinsed twice with 10mL of an ethanol / water mixture (1:5 ethanol:water by volume). The resulting wet crystals were dried at 25°C under a vacuum of 0.1 MPa for 17 hours to obtain 1.88g of revenacin Form A with a chemical purity of 99.79% and a yield of 94%. The X-ray powder diffraction pattern, DSC pattern, TGA pattern, and polarizing microscope image of the resulting revenacin Form A were essentially consistent with those in Example 1. The water content, as determined by Karl Fischer analysis, was 9.1% by weight.
[0113] Example 3:
[0114] 10 g of refenacin and 40 mL of an ethanol / water mixed solvent (ethanol:water volume ratio of 2:1) were mixed and heated to 52° C. to dissolve. The mixture was then cooled to 35° C., 0.2 g of seed crystals were added, and crystals were grown. 60 mL of a precipitation solvent (ethanol:water volume ratio of 1:4) was slowly added dropwise. After the addition was complete, the mixture was cooled to 25° C. to grow the crystals. The mixture was then filtered, and the filter cake was rinsed twice with 60 mL of an ethanol / water mixed solvent (ethanol:water volume ratio of 1:4). The resulting wet crystals were dried at 25° C. under a vacuum of 0.1 MPa for 2 h to obtain 9.30 g of refenacin Form A with a chemical purity of 99.87% and a yield of 92.6%. The water content, as determined by Karl Fischer analysis, was 9.3% by weight. The X-ray powder diffraction pattern, DSC pattern, TGA pattern, and polarizing microscope image of the resulting refenacin Form A were substantially consistent with those of Example 1.
[0115] Example 4:
[0116] An excess of refenacin was added to an acetone / water solution (6:1 by volume), mixed, and then filtered through a 0.25 μm needle filter to obtain a saturated refenacin solution. 0.5 mL of the saturated refenacin solution was diluted with 4.5 mL of the acetone / water solution and allowed to stand for very slow evaporation to obtain single crystals of refenacin hydrate.
[0117] The single crystal structure diagram of the revenacin hydrate single crystal is shown in FIG9 , and the XRD pattern calculated by single crystal simulation is shown in FIG10 .
[0118] Test Example 1: Dynamic Moisture Adsorption and Desorption Evaluation
[0119] Dynamic moisture sorption curves (also known as adsorption-desorption characteristic curves) were evaluated using a DVS Intrinsic (SMS). Approximately 30 mg of the sample prepared in Example 1 was scanned three times at room temperature (25°C): the first scan was a stepwise increase in relative humidity from 60% RH to 90% RH at a rate of 10% RH / step; the second scan was a stepwise decrease in relative humidity from 90% RH to 0% RH at a rate of 10% RH / step; and the third scan was a stepwise increase in relative humidity from 0% RH to 90% RH at a rate of 10% RH / step. The instrument was programmed to operate in mass change mode (dm / dt mode). When the mass change rate (dm / dt) was ≤ 0.005%, the instrument was programmed to switch to the next relative humidity level and maintain constant humidity (+ / - 10% RH).
[0120] The DVS (dynamic moisture adsorption / desorption curve) of the revenacin crystal form A of Example 1 is shown in FIG5 , which shows reversible adsorption / desorption characteristics and low hygroscopicity. When the humidity of the sample is gradually increased from 60% RH to 90% RH, the weight gain of the sample due to moisture is less than 0.4%; when the humidity of the sample is within the range of 30%-90% RH, the weight gain of the sample due to moisture is less than 2%, and the crystal form remains unchanged during the sampling process.
[0121] Test Example 2:
[0122] The wet crystal product of Example 1 was dried at a temperature of 30-35°C and a vacuum degree of -0.08 MPa. During the drying process, samples were taken to detect Karl Fischer moisture and XRPD. The results showed that when KF moisture = 17%, KF moisture = 8.9%, and KF moisture = 8.3%, the crystal form was all Form A; when the moisture content continued to decrease to KF = 7.1%, "miscellaneous peaks" began to appear in the XRPD spectrum, as shown in Figure 6, indicating that a crystal form transition occurred at a moisture content of KF = 7.1%, and mixed crystals appeared.
[0123] Test Example 3:
[0124] Revenacin Form A from Example 2 was dried in an oven at 30°C, a vacuum of 0.098 MPa-0.1 MPa, and a humidity of ≤20% for 24 hours, designated as Sample 1. Sample 1 was then placed in an oven at a humidity of 60-80% and a temperature of 25-30°C for 24 hours, designated as Sample 2. Samples 1 and 2 were tested for purity by XRPD, HPLC, and KF moisture content. The results are shown in the table below and Figure 7.
[0125] Combining Figure 7 and the table above, it can be seen that after dehydration, mixed crystals appear in revenacin Form A. However, when the humidity is changed, the mixed crystals absorb ambient moisture and transform back into Form A. During the temperature and humidity-mediated inter-form transformation process, the chemical purity of the crystalline form remains unchanged.
[0126] Test Example 4:
[0127] 4.1 The revenacin crystal form A prepared in Example 3 was packaged in a packaging material (the packaging material was a two-layer pharmaceutical low-density polyethylene bag inner packaging plus a layer of polyester aluminum polyethylene pharmaceutical packaging composite bag). The crystal form A with the packaging material was placed under the following influencing factors: high temperature (40°C), high humidity (92.5% RH), light (light 4500lx, near-ultraviolet ≥0.8×102μW / cm 2 ) and accelerated conditions (40°C / 75% RH), samples were taken at 0 days, 5 days, 10 days, and 35 days for testing the XRPD and HPLC purity of the samples. The results are listed in the table below.
[0128] Combined with the above table, it can be seen that the revenacin crystal form A of the present invention has a high temperature (40°C), high humidity (92.5% RH), light (light 4500lx, near ultraviolet ≥ 0.8×102μW / cm 2 ) and accelerated (40℃ / 75%RH) conditions, and the crystal form remains stable, showing good stability.
[0129] 4.2 The revenacin crystal form A prepared in Example 3 was packaged in a packaging material (the packaging material was a two-layer medicinal low-density polyethylene bag inner packaging plus a layer of polyester aluminum polyethylene pharmaceutical packaging composite bag). The packaged sample was placed at a temperature of 30°C / 35% RH and 40°C / 75% RH. The sample crystal form was sampled at 0 days, 3 months, and 6 months, respectively. The results are shown in the following table and Figure 8.
[0130] Combining the above table and Figure 8 , it can be seen that the revenacin of the present invention maintained its crystalline form and crystallinity when stored under accelerated conditions (40°C / 75% RH) for 3 and 6 months. Form A also maintained its crystalline form and crystallinity when stored under long-term conditions (30°C / 35% RH) for 6 months.
[0131] Test Example 5:
[0132] An appropriate amount of Form A prepared in Example 1 was used to evaluate its powder properties. The particle size distribution of the sample was examined using a Malvern 3000 particle size analyzer. The angle of repose of Form A was measured using a powder comprehensive properties tester. The bulk density and tap density of Form A were measured using a powder density tester.
[0133] The particle size distribution curve of Form A is shown in FIG11 . The particle size distribution curve of Form A of the present invention is unimodal and uniform; the main particle size is relatively large: D10 = 8.40 μm; D50 = 25.86 μm; and D90 = 53.59 μm.
[0134] The crystal form A of the present invention has better fluidity and the powder repose angle is 45 。 , bulk density (0.285g / cm 3 ) and tap density (0.494g / cm 3 ) are both high. The superior powder properties facilitate the preparation process, such as packaging and mixing of materials during the preparation process.
[0135] Test Example 6:
[0136] The revenacin Form A of Examples 1 and 3 were respectively dissolved in citric acid / sodium citrate buffered saline and the pH was controlled at 5.0±0.5 to prepare revenacin solutions, which were labeled as revenacin solutions 1# and 2#, respectively. After refenacin solutions 1# and 2# and commercially available samples were placed under accelerated conditions (40°C / 75% RH) for one month and long-term conditions (25°C±2°C / 40%±5% RH) for one or three months, less than 0.2% degradation was observed, and the total impurity content was less than 0.4%. Note: The commercially available sample is revenacin inhalation solution with the trade name YUPELRI; the increase in total impurities is the increase compared with the total impurities on day 0.
[0137] The revenacin crystal form A and its preparation method disclosed in this application can be implemented by those skilled in the art by referring to the content of this application and appropriately changing the raw materials, process parameters, and other links. The methods and products of this application have been described through preferred embodiments. It is obvious that relevant technical personnel can modify or appropriately change and combine the methods and products described herein without departing from the content, spirit, and scope of this application to implement the technology of this application. It is particularly important to point out that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included in the spirit, scope, and content of this application.
Claims
1. Refenacin crystal form A, characterized in that: The X-ray powder diffraction pattern of the refenacin crystal form A has characteristic peaks at diffraction angles 2θ of 4.7±0.2°, 9.2±0.2°, 12.7±0.2°, 18.2±0.2°, 18.5±0.2°, 20.7±0.2°, 21.3±0.2° and 25.6±0.2°; Preferably, the X-ray powder diffraction pattern of the refenacin crystalline form A further has at least one characteristic peak at a diffraction angle 2θ of 13.3±0.2°, 13.7±0.2°, 14.0±0.2°, 16.1±0.2°, 16.7±0.2°, 17.4±0.2°, 18.8±0.2°, 19.4±0.2°, 22.1±0.2°, 22.3±0.2°, 23.0±0.2°, 24.2±0.2° and 33.5±0.2°, in particular, the X-ray powder diffraction pattern of the refenacin crystalline form A has at least one characteristic peak at a diffraction angle 2θ of 4.7±0.2°. There are characteristic peaks at 0.2°, 9.2±0.2°, 12.7±0.2°, 13.3±0.2°, 13.7±0.2°, 14.0±0.2°, 16.1±0.2°, 16.7±0.2°, 17.4±0.2°, 18.2±0.2°, 18.5±0.2°, 18.8±0.2°, 19.4±0.2°, 20.7±0.2°, 21.3±0.2°, 22.1±0.2°, 22.3±0.2°, 23.0±0.2°, 24.2±0.2°, 25.6±0.2° and 33.5±0.2°; More preferably, the X-ray powder diffraction pattern of the refenacin crystal form A further has diffraction angles 2θ of 8.9±0.2°, 9.6±0.2°, 9.8±0.2°, 20.1±0.2°, 23.3±0.2°, 26.4±0.2°, 26.9±0.2°, 27.6±0.2°, 28.5±0.2°, 29.1±0.2°, 29. 4±0.2°, 30.1±0.2° and 32.9±0.2°, and in particular, the X-ray powder diffraction pattern of the refenacin crystal form A has a diffraction angle 2θ of 4.7±0.2°, 8.9±0.2°, 9.2±0.2°, 9.6±0.2°, 9.8±0.2°, 12.7±0.2°, 13.3±0.2°, 13.7 ±0.2°, 14.0±0.2°, 16.1±0.2°, 16.7±0.2°, 17.4±0.2°, 18.2±0.2°, 18.5±0.2°, 18.8±0.2°, 19.4±0.2°, 20.1±0.2°, 20.7±0.2°, 21.3±0.2°, 22.1±0.2°, 22.3±0.2° , there are characteristic peaks at 23.0±0.2°, 23.3±0.2°, 24.2±0.2°, 25.6±0.2°, 26.4±0.2°, 26.9±0.2°, 27.6±0.2°, 28.5±0.2°, 29.1±0.2°, 29.4±0.2°, 30.1±0.2°, 32.9±0.2° and 33.5±0.2°.
2. The revenacin crystal form A according to claim 1, characterized in that The X-ray powder diffraction pattern of the refenacin crystal form A is substantially as shown in FIG1 ; Preferably, the X-ray powder diffraction pattern of the refenacin crystal form A is shown in Figure 1.
3. The revenacin crystal form A according to claim 1 or 2, characterized in that The refenacin crystal form A has one or more of the following characteristics: 1) The refenacin crystal form A contains crystal water and is a hydrate crystal form, and the water content according to the Karl Fischer test is 8.0 wt%-10 wt%; 2) The revenacin crystal form A has an endothermic peak between 85-125°C, and the starting temperature of the endothermic peak is 88.3°C±5°C; 3) The DSC curve of the refenacin crystal form A is substantially as shown in FIG2 ; preferably, the DSC curve of the refenacin crystal form A is as shown in FIG2 ; 4) The refenacin crystal form A loses 9.2±0.2% of weight in the temperature range of 35-100°C; 5) The TGA curve of the refenacin crystal form A is substantially as shown in FIG3; preferably, refenacin The TGA curve of Form A is shown in Figure 3; 6) The appearance of the refenacin crystal form A is regular flakes; preferably, the polarized light microscopy PLM image of the refenacin crystal form A is shown in FIG4 ; and / or 7) The refenacin crystal form A is refenacin trihydrate.
4. A single crystal of revenacin hydrate, characterized in that: The single crystal belongs to the triclinic system, the space group is P-1, and its crystal axis The angles between the crystal planes are α=86.419(4)°, β=86.906(4)°, and γ=89.544(3)°. The number Z of asymmetric units in the unit cell is 2. Each unit cell contains one refenacin molecule and three water molecules.
5. The method for preparing the revenacin crystal form A according to any one of claims 1 to 3, characterized in that: The preparation method comprises the following steps: Step 1: mixing revenacin with a dissolving solvent, stirring, heating and dissolving, wherein the dissolving solvent is a mixed solvent of ethanol / water or a mixed solvent of acetone / water, for example, the dissolving solvent is a mixed solvent of ethanol / water; Step 2: Cooling to 35-45°C and stirring to grow crystals to obtain a refenacin suspension solution; Step 3: adding the precipitation solvent dropwise to the suspension solution in step 2 at 35-45°C; and Step 4: After cooling to 0-25°C and growing the crystals, the mixture is filtered and dried to constant weight to obtain the revenacin crystal form A.
6. The method for preparing revenacin crystal form A according to claim 5, characterized in that: The preparation method comprises one or more of the following features: 1) the mass volume ratio of refenacin to the dissolving solvent in step 1, in g / mL, is 1:4-5; II) adding revenacin to the dissolving solvent in step 1, stirring and heating to 50-55° C. to dissolve; III) the dissolving solvent is a mixed solvent of ethanol / water, preferably the dissolving solvent is a mixed solvent of ethanol and water in a volume ratio of 1-2:1, preferably a volume ratio of 2:1 or 1:1; or the dissolving solvent is a mixed solvent of acetone / water, preferably the dissolving solvent is a mixed solvent of acetone and water in a volume ratio of 1-4:1, for example, a volume ratio of 4:1, 3:1 or 2:1; IV) adding refenacin form A seed crystals in step 2; V) the amount of seed crystals added in step 2 is 1% to 2% by weight of revenacin, preferably 1% by weight; VI) the crystal growth time of the heat preservation stirring in step 2 is 1-4 hours, preferably 2 hours; the stirring rate is 100-800 rpm; preferably 400-600 rpm; VII) the precipitation solvent in step 3 is a mixed solvent of ethanol and water or a mixed solvent of acetone / water, for example, a mixed solvent in which the volume ratio of ethanol to water is 1:3-5 or a mixed solvent in which the volume ratio of acetone to water is 1:3-5; VIII) the mass volume ratio of revenacin to the precipitated solvent in step 3, in g / mL, is 1:3-6, preferably 1:4; IX) in step 3, the droplet acceleration rate of the precipitated solvent is nonlinear droplet addition, and the droplet acceleration is slow at first and then fast; preferably, the droplet addition time is 2-6h; more preferably, the droplet addition time is 3-4h; X) the crystal growing time in step 4 is 1-10h; XI) in step 4, the cooling rate is 0.1-2°C / min, preferably 0.5°C / min; and / or XII) In step 4, the drying is carried out at a temperature of 25-45° C. and a vacuum degree of 0.08 MPa-0.1 MPa for 2-20 hours.
7. The method for preparing a revenacin hydrate single crystal according to claim 4, characterized in that: The preparation method comprises the following steps: Step 1: adding an excess amount of refenacin to an acetone / water solution, mixing, filtering, and obtaining a saturated refenacin solution; and Step 2: dilute the saturated solution of refenacin with an acetone / water solution, and allow to stand for evaporation to obtain the refenacin hydrate single crystal.
8. The method for preparing the revenacin hydrate single crystal according to claim 7, characterized in that: The preparation method comprises one or more of the following features: i) the volume ratio of acetone to water in steps 1 and 2 is 5-7:1, for example 5:1, 6:1 or 7:1; and / or ii) filtering in step 1 through a needle filter membrane, preferably a 0.25 μm needle filter membrane; and / or iii) in step 2, the volume ratio of the saturated solution of refenacin to the acetone / water solution is 1:8-10, preferably 1:
9.
9. A pharmaceutical composition comprising the refenacin crystalline form A according to any one of claims 1 to 3 or the refenacin hydrate single crystal according to claim 4, and one or more pharmaceutically acceptable carriers.
10. The pharmaceutical composition according to claim 9, which optionally comprises one or more other therapeutic agents, wherein the other therapeutic agents refer to other pharmacologically active substances other than revifenacin, such as other muscarinic receptor antagonists or anticholinergic activities that can have a synergistic therapeutic effect with revifenacin.
11. Use of the refenacin crystalline form A according to any one of claims 1 to 3, the refenacin hydrate single crystal according to claim 4, or the pharmaceutical composition according to claim 9 or 10 in the preparation of a medicament for treating chronic obstructive pulmonary disease.
Citation Information
Patent Citations
Refinasin inhalation spray
CN117263848A
Ralfenasin trihydrate crystal form and preparation method thereof
CN117263849A
Process for the preparation of revefenacin, its salts and solid forms thereof
IN202011029286A
Crystalline forms of a biphenyl compound
US20070112027A1
Cited By
Crystal form of revefenacin triphenylacetate and preparation method therefor
WO2026144677A1
